IMMP trades 27.2% below Wall Street's consensus target of $4.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IMMP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Immutep Limited (IMMP) has a Wall Street consensus price target of $4.25, based on estimates from 3 covering analysts. With the stock currently trading at $3.34, this represents a potential upside of +27.2%. The company has a market capitalization of $25M.
Analyst price targets range from a low of $3.50 to a high of $5.00, representing a 35% spread in expectations. The median target of $4.25 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IMMP trades at a trailing P/E of -0.5x. Analysts expect EPS to grow +97.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NKTXNkarta, Inc. | $124M | $1.73 | $9.00 | +420.2% | Buy | — | 12 |
 AGENAgenus Inc. | $298M | $7.15 | $25.00 | +249.7% | Buy | 26.7x | 12 |
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $2.3B | $18.28 | $38.80 | +112.3% | Buy | — | 18 |
 TPVGTriplePoint Venture Growth BDC Corp. | $177M | $4.37 | $5.00 | +14.4% | Hold | 5.1x | 12 |
 FHTXFoghorn Therapeutics Inc. | $110M | $1.87 | $4.00 | +113.9% | Buy | — | 12 |
 BMYBristol-Myers Squibb Company | $126.9B | $62.14 | $66.08 | +6.3% | Hold | 9.6x | 42 |
 MRKMerck & Co., Inc. | $362.4B | $146.73 | $160.47 | +9.4% | Buy | 53.0x | 38 |
 REGNRegeneron Pharmaceuticals, Inc. | $93.2B | $904.35 | $887.79 | -1.8% | Buy | 13.4x | 49 |
 EXELExelixis, Inc. | $17.5B | $69.57 | $53.00 | -23.8% | Hold | 18.7x | 33 |
Quick answers to the most common questions about buying IMMP stock.
The consensus Wall Street price target for IMMP is $4.25, representing 27.2% upside from the current price of $3.34. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IMMP has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $4.25 implies 27.2% upside from current levels.
IMMP's current price is $3.34 with a consensus target of $4.25 (27.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for IMMP, while the most conservative target is $3.5. The consensus of $4.25 represents the median expectation. These targets typically reflect 12-month expectations.
IMMP is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IMMP stock forecast based on 3 Wall Street analysts shows a consensus price target of $4.25, with estimates ranging from $3.5 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IMMP, with a "Buy" consensus rating and $4.25 price target (27.2% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IMMP analyst price targets range from $3.5 to $5, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.25 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.